111 related articles for article (PubMed ID: 30055522)
1. Expression of galectin-1 and galectin-3 in renal cell carcinoma; immunohistochemical study.
Aboulhagag NA; El-Deek HEM; Sherif MF
Ann Diagn Pathol; 2018 Oct; 36():31-37. PubMed ID: 30055522
[TBL] [Abstract][Full Text] [Related]
2. Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker.
Dancer JY; Truong LD; Zhai Q; Shen SS
Arch Pathol Lab Med; 2010 Jan; 134(1):90-4. PubMed ID: 20073610
[TBL] [Abstract][Full Text] [Related]
3. Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster.
Saussez S; Nonclercq D; Laurent G; Wattiez R; André S; Kaltner H; Gabius HJ; Kiss R; Toubeau G
Histochem Cell Biol; 2005 Jan; 123(1):29-41. PubMed ID: 15609042
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of Galectin-3 in clear cell renal cell carcinoma.
Sakaki M; Fukumori T; Fukawa T; Elsamman E; Shiirevnyamba A; Nakatsuji H; Kanayama HO
J Med Invest; 2010 Feb; 57(1-2):152-7. PubMed ID: 20299755
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.
Huang CS; Tang SJ; Lee MH; Chang Wang CC; Sun GH; Sun KH
J Cell Mol Med; 2018 Dec; 22(12):5909-5918. PubMed ID: 30246456
[TBL] [Abstract][Full Text] [Related]
6. Expression and Distribution of Galectin-3 in Chromophobe and Papillary Carcinomas.
Cioca A; Muntean D; Bungardean C; Raica M; Cimpean AM
Anticancer Res; 2018 Jan; 38(1):259-263. PubMed ID: 29277781
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion.
Lai R; el Dabbagh L; Mourad WA
Mod Pathol; 1996 Jun; 9(6):690-5. PubMed ID: 8782209
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.
Zhan HC; Gudas LJ; Bok D; Rando R; Nanus DM; Tickoo SK
Clin Cancer Res; 2003 Oct; 9(13):4897-905. PubMed ID: 14581364
[TBL] [Abstract][Full Text] [Related]
9. Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma.
Jikuya R; Kishida T; Sakaguchi M; Yokose T; Yasui M; Hashizume A; Tatenuma T; Mizuno N; Muraoka K; Umemoto S; Kawai M; Yoshihara M; Nakamura Y; Miyagi Y; Sasada T
Cancer Immunol Immunother; 2020 Oct; 69(10):2041-2051. PubMed ID: 32424467
[TBL] [Abstract][Full Text] [Related]
10. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas.
François C; van Velthoven R; De Lathouwer O; Moreno C; Peltier A; Kaltner H; Salmon I; Gabius HJ; Danguy A; Decaestecker C; Kiss R
Am J Clin Pathol; 1999 Aug; 112(2):194-203. PubMed ID: 10439799
[TBL] [Abstract][Full Text] [Related]
11. Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study.
Bing Z; Lal P; Lu S; Ziober A; Tomaszewski JE
Ann Diagn Pathol; 2013 Feb; 17(1):58-62. PubMed ID: 22898056
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma.
Tsimafeyeu I; Demidov L; Stepanova E; Wynn N; Ta H
Scand J Urol Nephrol; 2011 Apr; 45(3):190-5. PubMed ID: 21329481
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Raica M; Cimpean AM; Anghel A
Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
[TBL] [Abstract][Full Text] [Related]
15. High expression of galectin-7 associates with poor overall survival in patients with non-metastatic clear-cell renal cell carcinoma.
Wang J; Liu Y; Yang Y; Xu Z; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2016 Jul; 7(27):41986-41995. PubMed ID: 27259255
[TBL] [Abstract][Full Text] [Related]
16. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
17. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival.
Merseburger AS; Kramer MW; Hennenlotter J; Serth J; Kruck S; Gracia A; Stenzl A; Kuczyk MA
World J Urol; 2008 Dec; 26(6):637-42. PubMed ID: 18594826
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers.
Young AN; Amin MB; Moreno CS; Lim SD; Cohen C; Petros JA; Marshall FF; Neish AS
Am J Pathol; 2001 May; 158(5):1639-51. PubMed ID: 11337362
[TBL] [Abstract][Full Text] [Related]
19. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma.
Straube T; Elli AF; Greb C; Hegele A; Elsässer HP; Delacour D; Jacob R
J Exp Clin Cancer Res; 2011 Sep; 30(1):89. PubMed ID: 21958686
[TBL] [Abstract][Full Text] [Related]
20. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
Kruck S; Bedke J; Hennenlotter J; Ohneseit PA; Kuehs U; Senger E; Sievert KD; Stenzl A
Oncol Rep; 2010 Jan; 23(1):159-63. PubMed ID: 19956876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
